The Precision Peptide Company Establishes Compliant U.S. Peptide Access with Telehealth and Prescription Infrastructure Partnership

About this update from Precision Peptide Company Inc

HighlightsSigned an agreement with a U.S.-based prescription telehealth and infrastructure partner to support compliant prescribing, fulfillment, and delivery of the Company's peptide productsBuilds on the Company's recently announced 503A compounding agreement, under which all peptides -including BPC-157- are to be 100% compounded in the United StatesPartner platform is trusted by more than 100 telehealth brands and is designed to align with U.S. legal, HIPAA, and pharmacy regulationsConnects licensed provider networks across all 50 U.S. states with prescription and pharmacy fulfillment workflowsSupports a compliant, nationwide U.S. infrastructure for prescription-based peptide access ahead of anticipated U.S. regulatory developmentsVancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has signed an agreement with a U.S.-based prescription telehealth and infrastructure partner (the "Partner") to support compliant prescribing, fulfillment, and delivery of the Company's peptide products.This news follows the Company's recently announced compounding agreement with a U.S.-based 503A sterile compounding pharmacy, under which all of the Company's peptides - including BPC-157 - are to be 100% compounded in the United States (see news release dated June 2, 2026). Today's announcement builds on that foundation by adding the prescription and telehealth infrastructure that connects licensed prescribers, patients, and pharmacy fulfillment within a single compliant pathway.The Partner operates a telehealth platform that is trusted by more than 100 telehealth brands and connects licensed provider networks across all 50 U.S. states with prescription workflows and pharmacy fulfillment. The platform is designed to align with U.S. legal, HIPAA, and pharmacy regulations.Pratap Sandhu, CEO of The Precision Peptide Company, commented:"We have secured 100% U.S. compounding for our peptides, and this agreement adds the prescription and telehealth infrastructure to deliver them effectively. Together, these two pieces position the Company to pursue compliant, prescription-based access to our products, subject to applicable regulatory developments. We are putting this in...

View stock analysis, news, and events for Precision Peptide Company Inc